Physician profile
Thomas P Evans
NPI 1841285228
$4,546.79
in general payments reported to CMS, 2019-2025
30 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $756 · 2021: $715 · 2022: $896 · 2023: $529 · 2024: $597 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,629.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $754.90 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $617.47 | 2021-2025 | |
| Amgen INC. | $553.14 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $505.14 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $497.52 | 2019-2025 | Verquvo, Gardasil 9, Steglatro |
| Lilly USA, LLC | $237.42 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Allergan, INC. | $207.69 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $196.58 | 2022-2024 | Rexulti |
| Pfizer INC. | $190.84 | 2020-2025 | |
| Biogen, INC. | $95.71 | 2025 | Skyclarys |
| Glaxosmithkline, LLC. | $86.03 | 2019-2024 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $81.25 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.08 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.25 | 2020-2024 | Jardiance |
| Abbott Laboratories | $48.99 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $40.03 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $38.21 | 2022 | |
| Neurocrine Biosciences, INC. | $32.95 | 2025 | |
| Dexcom, INC. | $32.17 | 2021 | |
| Sanofi Pasteur INC. | $29.40 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $22.29 | 2024 | Qelbree |
| Lundbeck LLC | $20.31 | 2025 | Rexulti |
| Corvista Health, INC. | $20.00 | 2025 | Corvista System |
| Teva Pharmaceuticals USA, INC. | $19.67 | 2024 | Austedo Xr |
| Axsome Therapeutics, INC. | $18.09 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $15.92 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.38 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.83 | 2025 | Caplyta |
| Pacira Therapeutics, INC. | $12.44 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.